Trials / Conditions / Lambert-Eaton Myasthenic Syndrome

Lambert-Eaton Myasthenic Syndrome

14 registered clinical trials studyying Lambert-Eaton Myasthenic Syndrome — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease NCT07478172	University of Missouri-Columbia	N/A
Recruiting	Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis NCT06441825	Heinrich-Heine University, Duesseldorf	—
Completed	Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes NCT05408702	Institut de Myologie, France	—
Completed	Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) NCT02970162	Catalyst Pharmaceuticals, Inc.	Phase 3
Completed	Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome NCT01511978	Jacobus Pharmaceutical	Phase 2
Completed	A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) NCT01377922	Catalyst Pharmaceuticals, Inc.	Phase 3
Active Not Recruiting	Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases NCT00716066	Fred Hutchinson Cancer Center	Phase 2
No Longer Available	Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome NCT01373333	The Cleveland Clinic	—
Completed	Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome NCT00004832	FDA Office of Orphan Products Development	N/A
Approved For Marketing	3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS) NCT00872950	Lahey Clinic	—
No Longer Available	Treatment of Lambert-Eaton Syndrome With 3,4 DAP NCT00704925	David P. Richman, MD	—
Approved For Marketing	Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myastheni NCT02189720	Catalyst Pharmaceuticals, Inc.	—
No Longer Available	Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine NCT00994916	David Lacomis, MD	—
Approved For Marketing	Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome NCT01825395	University of Colorado, Denver	—